Testosterone intranasal - Acerus Pharmaceuticals Corporation

Drug Profile

Testosterone intranasal - Acerus Pharmaceuticals Corporation

Alternative Names: CompleoTRT™; MPP 10; Nasobol; Natesto; TBS-1

Latest Information Update: 21 Dec 2016

Price : $50

At a glance

  • Originator Mattern Pharmaceuticals
  • Developer Acerus Pharmaceuticals
  • Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Eye disorder therapies; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Testosterone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Hypogonadism

Most Recent Events

  • 15 Dec 2016 Testosterone licensed to Hyundai Pharmaceutical for commercialisation in South Korea
  • 30 Nov 2016 Updated efficacy data from a phase III trial in Hypogonadism released by Aytu Biosciences
  • 05 Oct 2016 Launched for Hypogonadism in Canada (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top